课题基金 / 基金详情

AMBISOME VS AMPHOTERICIN B AND FLUCONAZOLE IN CRYPTOCOCCAL MENINGITIS IN AIDS

AMBISOME VS AMPHOTERICIN B AND FLUCONAZOLE IN CRYPTOCOCCAL MENINGITIS IN AIDS
Ambisome 对比两性霉素 B 和氟康唑治疗艾滋病隐球菌性脑膜炎
批准号：
6281667
负责人：
PHILIP C JOHNSON
金额：
$1.36万
依托单位：
UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON
依托单位国家：
美国
项目类别：
财政年份：
1997
资助国家：
美国
项目状态：
已结题
起止时间：
1997-12-01 至 1998-11-30
来源：
https://reporter.nih.gov/project-details/6281667
关键词：
AIDS AIDS therapy Cryptococcus amphotericin B bacterial meningitis clinical research combination chemotherapy drug screening /evaluation fluconazole human subject human therapy evaluation microorganism disease chemotherapy opportunistic infections

项目摘要

项目成果

PHILIP C JOHNSON的其他基金

相似基金

相关文献

中文摘要
翻译
这是一项III期、随机、双盲、多中心研究， 评价两种剂量AmBisome的安全性、耐受性和疗效 （脂质体阿替霉素B）与阿替霉素B，其次是氟康唑， 急性隐球菌性脑膜炎的首次发作， 艾滋病患者将接受AmBisome或阿替霉素B IV治疗2周， 接着是八周的氟康唑主要疗效结局为 在可评价的研究中评估的治疗成功发生率 亚群
英文摘要
This is a Phase III randomized, double-blind, multicenter study designed to evaluate the safety, tolerability and efficacy of two doses of AmBisome (Liposomal amphotericin B) versus amphotericin B, followed by fluconazole, for a first episode of acute cryptococcal meningitis in patients with AIDS. The patient will receive AmBisome or amphotericin B IV for 2 weeks, followed by eight weeks of fluconazole. The primary efficacy outcome is the incidence rate of the therapeutic success assessed in the evaluable subgroup.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
COMPARISON OF ANTIRETROVIRAL ACTIVITY OF 3 COMBINATION REGIMENS IN HIV+ PATIENTS
AMBISOME COMPARED WITH AMPHOTERICIN B FOR HISTOPLASMOSIS IN AIDS PTS
COMPARISON OF ANTIRETROVIRAL ACTIVITY OF 3 COMBINATION REGIMENS IN HIV+ PATIENTS
AMBISOME VS AMPHOTERICIN B AND FLUCONAZOLE IN CRYPTOCOCCAL MENINGITIS IN AIDS
海外基金